查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087707

T 細胞免疫療法市場：2026-2032 年全球市場預測，按療法、細胞來源、目標抗原、生產方法、患者類型、適應症和最終用戶分類。

T-Cell Immunotherapy Market by Therapy Type, Cell Source, Target Antigens, Manufacturing Method, Patient Type, Indication, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，T 細胞免疫療法市場將成長至 139 億美元，複合年成長率為 8.34%。

主要市場統計數據
基準年 2025 79.3億美元
預計年份：2026年 85.7億美元
預測年份 2032 139億美元
複合年成長率 (%) 8.34%

T細胞免疫療法曾經只是血液學領域的一項特殊創新，如今已發展成為精準腫瘤學的核心要素，這主要得益於CAR-T細胞療法、T細胞受體療法、腫瘤浸潤淋巴細胞療法以及新一代基因修飾T細胞平台的發展。其臨床基礎已被充分證實：T細胞能夠辨識惡性細胞，在體內增殖，並透過適當的活化、選擇或基因修飾，形成持久的免疫記憶。

全球癌症負擔日益加重，推動了市場發展。國際癌症研究機構 (IARC) 發布的 GLOBOCAN 2022 年預測顯示，全球將新增約 2,000 萬例癌症病例，並有 970 萬人死於癌症。自美國食品藥物管理局(FDA) 於 2017 年首次批准 CAR-T 細胞療法以來，該領域的應用範圍已擴展至淋巴瘤、白血病、多發性骨髓瘤和惡性黑色素瘤，並且研發管線正日益轉向固體癌、自體免疫疾病以及現成的異體移植療法。這些進展已使 T 細胞免疫療法成為癌症免疫療法、先進處方藥和個人化醫療領域中具有戰略意義的重要方向。

T細胞免疫療法前景的變革性變化

T細胞免疫療法的格局正因臨床療效的證實、生產的產業化以及從晚期挽救治療向早期治療的轉變而重塑。 FDA核准的Kymriah、Yescarta、Tecartus、Breyanzi、Abecma、Carvykti和Amtagvi等產品已證明，基因修飾或篩選的T細胞可在某些癌症中發揮顯著的治療作用，並且隨著適應症的擴展，適用患者範圍也在不斷擴大。

人工智慧對T細胞免疫療法的累積影響

人工智慧（AI）對T細胞免疫療法的各個階段都產生了越來越顯著的影響，從藥物發現和臨床開發到生產製造和病患監測。人工智慧驅動的生物資訊學，特別是與基因組學、轉錄組學、蛋白質組學、空間生物學和單細胞定序數據相結合時，可以輔助抗原發現、T細胞受體選擇、新抗原優先排序和腫瘤免疫逃脫預測。

全球T細胞免疫療法市場的關鍵區域洞察

北美仍然是T細胞免疫療法最成熟的地區，這得益於FDA良好的監管記錄、領先的學術癌症中心、完善的保險公司體係以及健全的生物技術資金籌措生態系統。美國在T細胞免疫療法的應用和臨床試驗密度方面處於領先地位，而加拿大則受益於協調的癌症網路、省級衛生技術評估流程以及不斷發展的細胞療法基礎設施。

關於引入T細胞免疫療法的關鍵群體特異性見解

隨著新加坡、泰國、馬來西亞、印尼、越南和菲律賓不斷加強其癌症治療、臨床研究、監管合規能力和醫療旅遊服務，東協正崛起為T細胞免疫療法區域成長中心。該地區的發展機會與價格合理且品質有保障的細胞處理、區域轉診途徑、監管協調以及與全球和本地細胞治療相關人員的夥伴關係密切相關。

影響T細胞免疫療法發展的主要國家趨勢

美國在商業化CAR-T細胞療法的引入、臨床試驗、FDA先例、認證治療中心以及真實世界數據（REW）的生成方面，均處於全球領先地位。加拿大正透過省級醫保覆蓋決策、跨保險合作以及學術生產舉措來擴大CAR-T細胞療法的可及性，而墨西哥則致力於構建專業的腫瘤服務、拓展私營部門的准入管道以及加強跨境合作。巴西在臨床研究能力、血液腫瘤學專業知識和癌症中心基礎設施方面均領先拉丁美洲。

為T細胞免疫療法領域的領導者提供的實用建議

產業領導者應優先考慮提供證據，證明與現有標準療法相比，新療法能夠帶來持續療效、延長總生存期、降低毒性、改善生活品質以及在真實世界中具有臨床價值。早期治療適應症、固體癌計畫、自體免疫疾病應用以及聯合治療均應以嚴謹的生物標記策略、完善的伴隨診斷規劃和明確的患者選擇標準為指導。

T細胞免疫療法的分析調查方法

本執行摘要基於公開權威來源的二手研究，包括監管資訊披露、臨床試驗註冊資訊來源、同行評審的腫瘤學文獻、衛生技術評估 (HTA) 文件、治療指南以及來自權威公共衛生機構的全球癌症統計數據。所有證據均經過資訊來源交叉核對，以確保準確性，並避免對市場規模估算、市場佔有率或預測做出不實斷言。

結論：T細胞免疫療法的新時代

T細胞免疫療法正進入一個新階段，其特點是臨床應用不斷拓展、技術不斷進步，以及對提高其可及性、成本效益、安全性和擴充性的需求日益成長。已通過核准的CAR-T細胞療法和TIL療法已展現出「活體藥物」的治療潛力，而下一代平台旨在將這些益處擴展到固體癌、早期治療以及某些免疫介導疾病。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 T細胞免疫療法市場：依治療方法分類

  • CAR-T療法
  • TCR療法
  • TIL療法

第8章 T細胞免疫療法市場：依細胞來源分類

  • 同種異體細胞
  • 自體細胞

第9章 T細胞免疫療法市場：以標靶抗原分類

  • BCMA靶點
  • CD19標靶
  • CD22標靶

第10章 T細胞免疫療法市場：依生產方法分類

  • Ex-Vivo
  • In-Vivo

第11章：T細胞免疫療法市場：依患者類型分類

  • 成年患者
  • 兒童患者

第12章 T細胞免疫療法市場：依適應症分類

  • 自體免疫疾病
    • 狼瘡
    • 類風濕性關節炎
  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 大腦和中樞神經系統
    • 肝癌
    • 黑色素瘤

第13章：T細胞免疫療法市場：依最終用戶分類

  • 癌症研究機構
  • 醫院
  • 專科診所

第14章 T細胞免疫療法市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：T細胞免疫療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 T細胞免疫療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Adaptimmune Therapeutics PLC
  • Alaunos Therapeutics, Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics PLC
  • BioNTech SE
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARGO Therapeutics, Inc.
  • CARsgen Therapeutics Holdings Limited
  • Cellectis SA
  • Celyad Oncology SA
  • Chimera Bioengineering
  • Dendreon Pharmaceuticals LLC
  • Eureka Therapeutics, Inc.
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics NV
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • LAVA Therapeutics NV
  • Lyell Immunopharma, Inc.
  • NeoTX Therapeutics Ltd.
  • Novartis AG
  • Oxford Vacmedix UK Limited
  • Poseida Therapeutics, Inc.
  • Sana Biotechnology, Inc.
  • TheraVectys SA
  • TScan Therapeutics, Inc.
  • Xenetic Biosciences, Inc.
Product Code: MRR-034B5003094B

The T-Cell Immunotherapy Market is projected to grow by USD 13.90 billion at a CAGR of 8.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.93 billion
Estimated Year [2026] USD 8.57 billion
Forecast Year [2032] USD 13.90 billion
CAGR (%) 8.34%

T-cell immunotherapy has moved from a specialized hematology innovation to a core pillar of precision oncology, led by CAR T-cell therapy, T-cell receptor therapies, tumor-infiltrating lymphocyte therapy, and next-generation engineered T-cell platforms. The clinical rationale is well established: T cells can recognize malignant cells, expand in vivo, and generate durable immune memory when appropriately activated, selected, or engineered.

Market momentum is supported by a rising global cancer burden, with IARC's GLOBOCAN 2022 estimating about 20 million new cancer cases and 9.7 million cancer deaths worldwide. Since the first U.S. FDA approvals of CAR T-cell therapies in 2017, the field has expanded across lymphoma, leukemia, multiple myeloma, and melanoma, while research pipelines increasingly target solid tumors, autoimmune disease, and off-the-shelf allogeneic approaches. This evolution positions T-cell immunotherapy as a strategically important segment of cancer immunotherapy, advanced therapy medicinal products, and personalized medicine.

Transformative Shifts in the T-Cell Immunotherapy Landscape

The T-cell immunotherapy landscape is being reshaped by clinical validation, manufacturing industrialization, and a shift from late-line rescue therapy toward earlier treatment settings. FDA-approved products such as Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Amtagvi demonstrate that engineered or selected T cells can deliver meaningful responses in selected cancers, while label expansions continue to broaden eligible patient populations.

The next transformation is operational. Developers and healthcare systems are investing in closed-system manufacturing, cryopreservation, decentralized collection networks, and improved release testing to reduce vein-to-vein time. At the same time, allogeneic T-cell therapies, gene-editing tools, dual-target constructs, safety switches, and armored CAR designs are being evaluated to address relapse, antigen escape, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and cost barriers in the T-cell immunotherapy landscape.

Cumulative Impact of Artificial Intelligence on T-Cell Immunotherapy

Artificial intelligence is increasingly influencing T-cell immunotherapy across discovery, clinical development, manufacturing, and patient monitoring. AI-enabled bioinformatics can support antigen discovery, T-cell receptor selection, neoantigen prioritization, and prediction of tumor immune escape, particularly when integrated with genomics, transcriptomics, proteomics, spatial biology, and single-cell sequencing data.

In manufacturing, machine learning can help identify process variables linked to cell phenotype, expansion, potency, and batch consistency. In clinical practice, AI can support patient selection, toxicity risk stratification for cytokine release syndrome or neurotoxicity, imaging review, and real-world evidence generation. The cumulative impact is not a replacement for biological validation; it is a faster, data-driven framework for designing safer, more scalable, and more personalized T-cell therapies while strengthening quality control and clinical decision support.

Key Regional Insights Across Global T-Cell Immunotherapy Markets

North America remains the most mature region for T-cell immunotherapy, supported by FDA regulatory experience, major academic cancer centers, payer frameworks, and a deep biotechnology financing ecosystem. The United States leads adoption and clinical trial density, while Canada benefits from coordinated cancer networks, provincial health technology assessment processes, and growing cell therapy infrastructure.

Europe is advancing through EMA-approved advanced therapy medicinal products, national reimbursement pathways, cross-border research networks, and strong manufacturing capabilities in Germany, France, Italy, Spain, and the United Kingdom. Asia-Pacific is one of the fastest-developing regions, led by China's high clinical trial volume, Japan's regenerative medicine framework, South Korea's biomanufacturing strength, India's cost-focused innovation, and Australia's translational research networks.

Latin America, the Middle East, and Africa are earlier in commercialization but strategically important for long-term access. Brazil and Mexico are building oncology access, referral networks, and trial capacity; Middle Eastern health systems, particularly in high-investment Gulf countries, are expanding specialized hospitals, genomic medicine, and advanced oncology services; and African markets are prioritizing partnerships, diagnostics, hematology-oncology infrastructure, workforce training, and referral pathways to expand access to T-cell immunotherapy over time.

Key Group Insights for T-Cell Immunotherapy Adoption

ASEAN is emerging as a regional growth corridor for T-cell immunotherapy as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines strengthen oncology care, clinical research, regulatory capacity, and medical tourism services. The region's opportunity is tied to affordability, quality-assured cell processing, regional referral pathways, regulatory harmonization, and partnerships with global and local cell therapy stakeholders.

The European Union provides a structured environment for advanced therapy medicinal products through centralized EMA review, pharmacovigilance requirements, health technology assessment alignment, and cross-border research funding. The GCC is investing in high-acuity cancer centers, precision medicine, genomics programs, and international hospital partnerships, creating a foundation for advanced cell therapy adoption in selected tertiary care settings.

BRICS countries are important for patient scale, manufacturing diversification, clinical development, and cost innovation, particularly China, India, and Brazil, while South Africa and Russia contribute scientific capability and regional access considerations. G7 countries continue to anchor clinical evidence generation, reimbursement debate, regulatory precedent, and specialized treatment-center networks. NATO countries overlap significantly with advanced Western healthcare systems, supporting supply chain resilience, research collaboration, cold-chain readiness, and biomanufacturing security for cell and gene therapies.

Key Country Insights Shaping T-Cell Immunotherapy Growth

The United States is the global benchmark for commercial CAR T-cell therapy adoption, clinical trials, FDA precedent, accredited treatment centers, and real-world evidence generation. Canada is expanding access through provincial reimbursement decisions, coordinated cancer agencies, and academic manufacturing initiatives, while Mexico is developing specialized oncology services, private-sector access pathways, and cross-border collaboration. Brazil leads Latin America in clinical research capacity, hematology-oncology expertise, and cancer center infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong oncology systems with active health technology assessment, managed access programs, and hospital-based treatment expertise. Germany and France remain important for advanced therapy manufacturing and reimbursement evaluation, the United Kingdom supports early access and clinical research infrastructure, and Italy and Spain are strengthening regional treatment-center networks. Russia maintains scientific and clinical capabilities but faces access, financing, and international collaboration constraints.

In Asia-Pacific, China has become a major clinical development hub for CAR T-cell therapy, supported by large patient populations, active investigator-led studies, and expanding regulatory experience. India is advancing cost-efficient indigenous cell therapy models and local manufacturing approaches, Japan benefits from a supportive regenerative medicine environment and established oncology care, South Korea is strong in biologics and cell therapy manufacturing, and Australia supports early-phase translational research through leading cancer institutes, public health research funding, and clinical trial networks.

Actionable Recommendations for T-Cell Immunotherapy Leaders

Industry leaders should prioritize evidence generation that demonstrates durable response, overall survival benefit, manageable toxicity, quality-of-life improvement, and real-world value versus existing standards of care. Earlier-line indications, solid tumor programs, autoimmune applications, and combination strategies should be pursued with disciplined biomarker strategies, robust companion diagnostic planning, and clear patient-selection criteria.

Executives should also invest in scalable manufacturing, digital chain-of-identity and chain-of-custody systems, automated quality control, validated potency assays, and resilient cryogenic logistics. Partnerships with academic centers, hospitals, payers, contract development and manufacturing organizations, diagnostic laboratories, and public health stakeholders can reduce commercialization friction. To improve access, organizations should evaluate outcomes-based reimbursement, regional manufacturing hubs, technology transfer models, and tiered market strategies that align advanced T-cell immunotherapy innovation with health system affordability.

Research Methodology for T-Cell Immunotherapy Analysis

This executive summary is based on secondary research from publicly available, authoritative sources, including regulatory agency disclosures, clinical trial registries, peer-reviewed oncology literature, health technology assessment documents, treatment guidelines, and global cancer statistics from recognized public health organizations. Evidence was cross-checked across multiple sources to ensure accuracy and to avoid unsupported market estimation, sizing, share, or forecasting claims.

The research framework assessed approved therapies, pipeline direction, regional regulatory environments, reimbursement trends, manufacturing models, technology adoption, and clinical development activity. Insights were synthesized using qualitative market analysis, competitive benchmarking, regulatory review, and healthcare system assessment, with emphasis on data-backed developments in CAR T-cell therapy, TCR therapy, TIL therapy, allogeneic cell therapy, gene-edited cell therapy, and AI-enabled cell therapy innovation.

Conclusion: The Next Era of T-Cell Immunotherapy

T-cell immunotherapy is entering a new phase defined by broader clinical use, more sophisticated engineering, and increasing pressure to improve access, cost, safety, and scalability. Approved CAR T-cell and TIL therapies have validated the therapeutic potential of living medicines, while next-generation platforms aim to extend benefit into solid tumors, earlier lines of care, and selected immune-mediated diseases.

The field's long-term progress will depend on manufacturing efficiency, biomarker-driven development, payer confidence, global infrastructure, equitable referral pathways, and responsible integration of artificial intelligence. Organizations that combine rigorous science with operational excellence, regulatory discipline, and access-focused commercialization will be best positioned to lead the next era of oncology immunotherapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. T-Cell Immunotherapy Market, by Therapy Type

  • 7.1. CAR-T Therapy
  • 7.2. TCR Therapy
  • 7.3. TIL Therapy

8. T-Cell Immunotherapy Market, by Cell Source

  • 8.1. Allogeneic Cells
  • 8.2. Autologous Cells

9. T-Cell Immunotherapy Market, by Target Antigens

  • 9.1. BCMA Targeting
  • 9.2. CD19 Targeting
  • 9.3. CD22 Targeting

10. T-Cell Immunotherapy Market, by Manufacturing Method

  • 10.1. Ex-Vivo
  • 10.2. In-Vivo

11. T-Cell Immunotherapy Market, by Patient Type

  • 11.1. Adult Patients
  • 11.2. Pediatric Patients

12. T-Cell Immunotherapy Market, by Indication

  • 12.1. Autoimmune Diseases
    • 12.1.1. Lupus
    • 12.1.2. Rheumatoid Arthritis
  • 12.2. Hematological Malignancies
    • 12.2.1. Leukemia
    • 12.2.2. Lymphoma
    • 12.2.3. Myeloma
  • 12.3. Solid Tumors
    • 12.3.1. Brain & Central Nervous System
    • 12.3.2. Liver Cancer
    • 12.3.3. Melanoma

13. T-Cell Immunotherapy Market, by End-User

  • 13.1. Cancer Research Institutes
  • 13.2. Hospitals
  • 13.3. Specialty Clinics

14. T-Cell Immunotherapy Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. T-Cell Immunotherapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. T-Cell Immunotherapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Adaptimmune Therapeutics PLC
  • 18.2. Alaunos Therapeutics, Inc.
  • 18.3. Allogene Therapeutics, Inc.
  • 18.4. Amgen Inc.
  • 18.5. AstraZeneca PLC
  • 18.6. Atara Biotherapeutics, Inc.
  • 18.7. Autolus Therapeutics PLC
  • 18.8. BioNTech SE
  • 18.9. bluebird bio, Inc.
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. CARGO Therapeutics, Inc.
  • 18.12. CARsgen Therapeutics Holdings Limited
  • 18.13. Cellectis SA
  • 18.14. Celyad Oncology SA
  • 18.15. Chimera Bioengineering
  • 18.16. Dendreon Pharmaceuticals LLC
  • 18.17. Eureka Therapeutics, Inc.
  • 18.18. Fate Therapeutics, Inc.
  • 18.19. Gilead Sciences, Inc.
  • 18.20. Immatics N.V.
  • 18.21. Innovative Cellular Therapeutics
  • 18.22. Iovance Biotherapeutics, Inc.
  • 18.23. Johnson & Johnson
  • 18.24. LAVA Therapeutics N.V.
  • 18.25. Lyell Immunopharma, Inc.
  • 18.26. NeoTX Therapeutics Ltd.
  • 18.27. Novartis AG
  • 18.28. Oxford Vacmedix UK Limited
  • 18.29. Poseida Therapeutics, Inc.
  • 18.30. Sana Biotechnology, Inc.
  • 18.31. TheraVectys SA
  • 18.32. TScan Therapeutics, Inc.
  • 18.33. Xenetic Biosciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL T-CELL IMMUNOTHERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL T-CELL IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAR-T THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAR-T THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAR-T THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TCR THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TCR THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TCR THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TIL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TIL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TIL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOLOGOUS CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOLOGOUS CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOLOGOUS CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BCMA TARGETING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BCMA TARGETING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BCMA TARGETING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CD19 TARGETING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CD19 TARGETING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CD19 TARGETING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CD22 TARGETING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CD22 TARGETING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CD22 TARGETING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EX-VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EX-VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EX-VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IN-VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IN-VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IN-VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUPUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN & CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN & CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN & CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVER CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 166. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 169. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 170. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 171. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 175. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 203. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 204. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 207. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 214. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 215. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 236. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 237. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 238. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 248. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 249. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 253. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 254. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 255. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 258. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 259. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 260. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 263. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 264. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 265. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 277. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 280. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 281. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 282. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 285. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 286. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 287. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 288. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 299. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 309. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 310. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 313. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 314. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 315. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 317. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 318. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 319. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 320. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 324. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 325. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 326. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 335. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 336. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 337. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 339. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 340. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 341. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 343. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 346. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 347. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION)
  • TABLE 348. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 350. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 351. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 352. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 353. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 354. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 355. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 357. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TARGET ANTIGENS, 2018-2032 (USD MILLION)
  • TABLE 358. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MANUFACTURING METHOD, 2018-2032 (USD MILLION